MHC II (HLA-DRA)(IPO-10) , Biotin conjugate , 0.1mg / mL

MAb IPO-10 defines the antigen that appears on B cell progenitors following HLA-DR and preceding CD10 , CD19 , CD22 , CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi , Raji , Namalva , EB-3 , RPMI-8226 (50% of cells). The MAb does not label T cell lines , blood granulocytes , thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This MAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AM mL cells and in a majority of Hodgkin's disease cases a significant percentage of affected lymph node cells were detected. Primary antibodies are available purified , or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets , because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.